Nektar Therapeutics
LSE: 0UNL.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Howard W. Robin
- Employees
- 61
- Headquarters
- San Francisco, United States
- IPO year
- 2018
- Market cap
- $1.7B
- Website
- https://www.nektar.com
Loading 0UNL…
Loading profile data…Frequently asked questions about 0UNL
What does Nektar Therapeutics (0UNL.L) do?
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
Where does 0UNL.L trade?
Nektar Therapeutics (0UNL.L) trades on the London Stock Exchange.
What sector is 0UNL.L in?
Nektar Therapeutics (0UNL.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Nektar Therapeutics?
Howard W. Robin is the chief executive officer of Nektar Therapeutics (0UNL.L).
Where is Nektar Therapeutics headquartered?
Nektar Therapeutics is headquartered in United States.
Does 0UNL.L pay a dividend?
Nektar Therapeutics (0UNL.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0UNL.L go public?
Nektar Therapeutics (0UNL.L) completed its initial public offering in 2018.